Brain, Vol. 113, No. 5, 1477-1489, 1990
© 1990 Guarantors of Brain
research-article |
BREAKDOWN OF THE BLOOD-BRAIN BARRIER PRECEDES SYMPTOMS AND OTHER MRI SIGNS OF NEW LESIONS IN MULTIPLE SCLEROSIS
PATHOGENETIC AND CLINICAL IMPLICATIONS
1The Multiple Sclerosis NMR Research Group, Institute of Neurology London, UK 2The National Hospitals for Nervous Diseases, Queen Square London, UK
Correspondence to:
Correspondence to Dr Allan G. Kermode, NMR Research Group. Institute of Neurology, Queen Square, London WC1N 3BG, UK.
From an extensive serial magnetic resonance imaging (MRI) study in multiple sclerosis (MS) we have identified 4 cases in which disruption of the blood-brain barrier, as detected by gadolinium-DTPA enhancement, preceded other MRI abnormalities and in 1 case clinical evidence of the new lesion. This supports the view that a defect in the blood-brain barrier, and therefore inflammation, is an early and possibly crucial event in the pathogenesis of the new lesion in MS. These cases showed a marked discrepancy between MRI abnormality and symptoms. The mechanisms contributing to this disparity are discussed, and it is concluded that far from being surprising it is to be expected.
Received August 11, 1989. Accepted November 8, 1989.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. Gaultier, X. Wu, N. Le Moan, S. Takimoto, G. Mukandala, K. Akassoglou, W. M. Campana, and S. L. Gonias Low-density lipoprotein receptor-related protein 1 is an essential receptor for myelin phagocytosis J. Cell Sci., April 15, 2009; 122(8): 1155 - 1162. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Rithidech, L Honikel, M Milazzo, D Madigan, R Troxell, and L. Krupp Protein expression profiles in pediatric multiple sclerosis: potential biomarkers Multiple Sclerosis, April 1, 2009; 15(4): 455 - 464. [Abstract] [PDF] |
||||
![]() |
P Zamboni, R Galeotti, E Menegatti, A M Malagoni, G Tacconi, S Dall'Ara, I Bartolomei, and F Salvi Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis J. Neurol. Neurosurg. Psychiatry, April 1, 2009; 80(4): 392 - 399. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. T. Okuda, E. M. Mowry, A. Beheshtian, E. Waubant, S. E. Baranzini, D. S. Goodin, S. L. Hauser, and D. Pelletier Incidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome Neurology, March 3, 2009; 72(9): 800 - 805. [Abstract] [Full Text] [PDF] |
||||
![]() |
D Bar-Zohar, F Agosta, D Goldstaub, and M Filippi Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives Multiple Sclerosis, July 1, 2008; 14(6): 719 - 727. [Abstract] [PDF] |
||||
![]() |
J Kraus, K Voigt, A. Schuller, M Scholz, K. Kim, M Schilling, W. Schabitz, P Oschmann, and B Engelhardt Interferon-{beta} stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro Multiple Sclerosis, July 1, 2008; 14(6): 843 - 852. [Abstract] [PDF] |
||||
![]() |
W. Beghdadi, A. Porcherie, B. S. Schneider, D. Dubayle, R. Peronet, M. Huerre, T. Watanabe, H. Ohtsu, J. Louis, and S. Mecheri Inhibition of histamine-mediated signaling confers significant protection against severe malaria in mouse models of disease J. Exp. Med., February 18, 2008; 205(2): 395 - 408. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Forster, T. Kahles, S. Kietz, and D. Drenckhahn Dexamethasone induces the expression of metalloproteinase inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line cEND J. Physiol., May 1, 2007; 580(3): 937 - 949. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Adams, J. Bauer, M. J. Flick, S. L. Sikorski, T. Nuriel, H. Lassmann, J. L. Degen, and K. Akassoglou The fibrin-derived {gamma}377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease J. Exp. Med., March 19, 2007; 204(3): 571 - 582. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Zamboni The Big Idea: Iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis J R Soc Med, November 1, 2006; 99(11): 589 - 593. [Full Text] [PDF] |
||||
![]() |
A. T. Argaw, Y. Zhang, B. J. Snyder, M.-L. Zhao, N. Kopp, S. C. Lee, C. S. Raine, C. F. Brosnan, and G. R. John IL-1beta Regulates Blood-Brain Barrier Permeability via Reactivation of the Hypoxia-Angiogenesis Program J. Immunol., October 15, 2006; 177(8): 5574 - 5584. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Gupta, J M Solomon, T A Tasciyan, M M Cao, R D Stone, J L Ostuni, J M Ohayon, P A Muraro, J A Frank, N D Richert, et al. Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis Multiple Sclerosis, December 1, 2005; 11(6): 658 - 668. [Abstract] [PDF] |
||||
![]() |
P S Piraino, T A Yednock, S B Freedman, E K Messersmith, M A Pleiss, and S J Karlik Suppression of acute experimental allergic encephalomyelitis with a small molecule inhibitor of {alpha}4 integrin Multiple Sclerosis, December 1, 2005; 11(6): 683 - 690. [Abstract] [PDF] |
||||
![]() |
E. East, D. Baker, G. Pryce, H. R. Lijnen, M. L. Cuzner, and D. Gveric A Role for the Plasminogen Activator System in Inflammation and Neurodegeneration in the Central Nervous System during Experimental Allergic Encephalomyelitis Am. J. Pathol., August 1, 2005; 167(2): 545 - 554. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J Jimenez, W. Jy, L. M Mauro, L. L Horstman, E. R Ahn, Y. S Ahn, and A. Minagar Elevated endothelial microparticle--monocyte complexes induced by multiple sclerosis plasma and the inhibitory effects of interferon-{beta}1b on release of endothelial microparticles, formation and transendothelial migration of monocyte-endothelial microparticle complexes Multiple Sclerosis, June 1, 2005; 11(3): 310 - 315. [Abstract] [PDF] |
||||
![]() |
M. Hardmeier, S. Wagenpfeil, P. Freitag, E. Fisher, R. A. Rudick, M. Kooijmans, M. Clanet, E. W. Radue, L. Kappos, and for the European IFNss-1a in Relapsing MS Dose Com Rate of brain atrophy in relapsing MS decreases during treatment with IFN{beta}-1a Neurology, January 25, 2005; 64(2): 236 - 240. [Abstract] [Full Text] [PDF] |
||||
![]() |
J Sastre-Garriga, M Comabella, L Brieva, A Rovira, M Tintore, and X Montalban Decreased MMP-9 production in primary progressive multiple sclerosis patients Multiple Sclerosis, August 1, 2004; 10(4): 376 - 380. [Abstract] [PDF] |
||||
![]() |
R. A. Adams, M. Passino, B. D. Sachs, T. Nuriel, and K. Akassoglou Fibrin Mechanisms and Functions in Nervous System Pathology Mol. Interv., June 1, 2004; 4(3): 163 - 176. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Akassoglou, R. A. Adams, J. Bauer, P. Mercado, V. Tseveleki, H. Lassmann, L. Probert, and S. Strickland Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis PNAS, April 27, 2004; 101(17): 6698 - 6703. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Minagar and J S. Alexander Blood-brain barrier disruption in multiple sclerosis Multiple Sclerosis, December 1, 2003; 9(6): 540 - 549. [Abstract] [PDF] |
||||
![]() |
Y. Ge, R. I. Grossman, J. S. Babb, J. He, and L. J. Mannon Dirty-Appearing White Matter in Multiple Sclerosis: Volumetric MR Imaging and Magnetization Transfer Ratio Histogram Analysis AJNR Am. J. Neuroradiol., November 1, 2003; 24(10): 1935 - 1940. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Bagnato, N. Jeffries, N. D. Richert, R. D. Stone, J. M. Ohayon, H. F. McFarland, and J. A. Frank Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years Brain, August 1, 2003; 126(8): 1782 - 1789. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Gveric, B. Herrera, A. Petzold, D. A. Lawrence, and M. L. Cuzner Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors Brain, July 1, 2003; 126(7): 1590 - 1598. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Boven, N. Vergnolle, S. D. Henry, C. Silva, Y. Imai, J. Holden, K. Warren, M. D. Hollenberg, and C. Power Up-Regulation of Proteinase-Activated Receptor 1 Expression in Astrocytes During HIV Encephalitis J. Immunol., March 1, 2003; 170(5): 2638 - 2646. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Waubant, D. Goodkin, A. Bostrom, P. Bacchetti, J. Hietpas, R. Lindberg, and D. Leppert IFN{beta} lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS Neurology, January 14, 2003; 60(1): 52 - 57. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Rosenberg Matrix Metalloproteinases and Neuroinflammation in Multiple Sclerosis Neuroscientist, December 1, 2002; 8(6): 586 - 595. [Abstract] [PDF] |
||||
![]() |
P. Esposito, N. Chandler, K. Kandere, S. Basu, S. Jacobson, R. Connolly, D. Tutor, and T. C. Theoharides Corticotropin-Releasing Hormone and Brain Mast Cells Regulate Blood-Brain-Barrier Permeability Induced by Acute Stress J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1061 - 1066. [Abstract] [Full Text] [PDF] |
||||
![]() |
E L. Hoogervorst, C H Polman, and F Barkhof Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone Multiple Sclerosis, October 1, 2002; 8(5): 415 - 419. [Abstract] [PDF] |
||||
![]() |
I McDonald Multiple sclerosis in its European matrix Multiple Sclerosis, June 1, 2002; 8(3): 181 - 191. [PDF] |
||||
![]() |
D. Buljevac, H. Z. Flach, W. C. J. Hop, D. Hijdra, J. D. Laman, H. F. J. Savelkoul, F. G. A. van der Meche, P. A. van Doorn, and R. Q. Hintzen Prospective study on the relationship between infections and multiple sclerosis exacerbations Brain, May 1, 2002; 125(5): 952 - 960. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Wang and K. Walsh Multiple Ring-Enhancing Lesions in a Child With Relapsing Multiple Sclerosis J Child Neurol, January 1, 2002; 17(1): 69 - 72. [Abstract] [PDF] |
||||
![]() |
P. A. Brex, P. D. Molyneux, P. Smiddy, F. Barkhof, M. Filippi, T. A. Yousry, D. Hahn, Y. Rolland, O. Salonen, C. Pozzilli, et al. The effect of IFN{beta}-1b on the evolution of enhancing lesions in secondary progressive MS Neurology, December 26, 2001; 57(12): 2185 - 2190. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. P. Lindberg, C. J. A. De Groot, L. Montagne, P. Freitag, P. van der Valk, L. Kappos, and D. Leppert The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis Brain, September 1, 2001; 124(9): 1743 - 1753. [Abstract] [Full Text] [PDF] |
||||
![]() |
N C Silver, P S Tofts, M R Symms, G J Barker, A J Thompson, and D H Miller Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study Multiple Sclerosis, April 1, 2001; 7(2): 75 - 82. [Abstract] [PDF] |
||||
![]() |
P A Brex, K A Miszkiel, J I O'Riordan, G T Plant, I F Moseley, A J Thompson, and D H Miller Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI J. Neurol. Neurosurg. Psychiatry, March 1, 2001; 70(3): 390 - 393. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. P. Leist, M. I. Gobbini, J. A. Frank, and H. F. McFarland Enhancing Magnetic Resonance Imaging Lesions and Cerebral Atrophy in Patients With Relapsing Multiple Sclerosis Arch Neurol, January 1, 2001; 58(1): 57 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Pender, P. A. Csurhes, J. M. Greer, P. D. Mowat, R. D. Henderson, K. D. Cameron, D. M. Purdie, P. A. McCombe, and M. F. Good Surges of Increased T Cell Reactivity to an Encephalitogenic Region of Myelin Proteolipid Protein Occur More Often in Patients with Multiple Sclerosis Than in Healthy Subjects J. Immunol., November 1, 2000; 165(9): 5322 - 5331. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Saindane, Y. Ge, J. K. Udupa, J. S. Babb, L. J. Mannon, and R. I. Grossman The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS Neurology, July 12, 2000; 55(1): 61 - 65. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Poser Trauma to the Central Nervous System May Result in Formation or Enlargement of Multiple Sclerosis Plaques Arch Neurol, July 1, 2000; 57(7): 1074 - 1077. [Full Text] [PDF] |
||||
![]() |
M. D. Carrithers, I. Visintin, S. J. Kang, and C. A. Janeway Jr Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment Brain, June 1, 2000; 123(6): 1092 - 1101. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. A. Rice, M. Filippi, and G. Comi Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial Neurology, March 14, 2000; 54(5): 1145 - 1155. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. H. Secor, W. E. Secor, C.-A. Gutekunst, and M. A. Brown Mast Cells Are Essential for Early Onset and Severe Disease in a Murine Model of Multiple Sclerosis J. Exp. Med., March 6, 2000; 191(5): 813 - 822. [Abstract] [Full Text] [PDF] |
||||
![]() |
F Bagnato, A Tancredi, N Richert, C Gasperini, S Bastianello, C Bash, H McFarland, C Pozzilli, and J A Frank Contrast-enhanced magnetic resonance activity in relapsing remitting multiple sclerosis patients: a short term natural history study Multiple Sclerosis, February 1, 2000; 6(1): 43 - 49. [Abstract] [PDF] |
||||
![]() |
M Rovaris, B Viti, G Ciboddo, S Gerevini, R Capra, G Iannucci, G Comi, and M Filippi Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study J. Neurol. Neurosurg. Psychiatry, February 1, 2000; 68(2): 170 - 177. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Miki, R. I. Grossman, J. K. Udupa, L. Wei, M. Polansky, L. J. Mannon, and D. L. Kolson Relapsing-Remitting Multiple Sclerosis: Longitudinal Analysis of MR Images-Lack of Correlation between Changes in T2 Lesion Volume and Clinical Findings Radiology, November 1, 1999; 213(2): 395 - 399. [Abstract] [Full Text] |
||||
![]() |
W I McDonald Physicians, subsequence and consequence J. Neurol. Neurosurg. Psychiatry, September 1, 1999; 67(3): 282 - 289. [Full Text] |
||||
![]() |
N. Tubridy, P. O. Behan, R. Capildeo, A. Chaudhuri, R. Forbes, C. P. Hawkins, R. A. C. Hughes, J. Palace, B. Sharrack, R. Swingler, et al. The effect of anti-{alpha}4 integrin antibody on brain lesion activity in MS Neurology, August 1, 1999; 53(3): 466 - 466. [Abstract] [Full Text] |
||||
![]() |
M. A. A. van Walderveen, L. Truyen, B. W. van Oosten, J. A. Castelijns, G. J. Lycklama a Nijeholt, J. H. T. M. van Waesberghe, C. Polman, and F. Barkhof Development of Hypointense Lesions on T1-Weighted Spin-Echo Magnetic Resonance Images in Multiple Sclerosis: Relation to Inflammatory Activity Arch Neurol, March 1, 1999; 56(3): 345 - 351. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Myhr, T. Riise, F. E. G. Lilleas, T. G. Beiske, E. G. Celius, A. Edland, D. Jensen, J. P. Larsen, R. Nilsen, M. W. Nortvedt, et al. Interferon-{alpha}2a reduces MRI disease activity in relapsing-remitting multiple sclerosis Neurology, March 1, 1999; 52(5): 1049 - 1049. [Abstract] [Full Text] |
||||
![]() |
H. I. McFarland, A. A. Lobito, M. M. Johnson, J. T. Nyswaner, J. A. Frank, G. R. Palardy, N. Tresser, C. P. Genain, J. P. Mueller, L. A. Matis, et al. Determinant Spreading Associated with Demyelination in a Nonhuman Primate Model of Multiple Sclerosis J. Immunol., February 15, 1999; 162(4): 2384 - 2390. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kidd, F. Barkhof, R. McConnell, P. R. Algra, I. V. Allen, and T. Revesz Cortical lesions in multiple sclerosis Brain, January 1, 1999; 122(1): 17 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Edwards, M Zvartau, H Clarke, W Irving, and L D Blumhardt Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, June 1, 1998; 64(6): 736 - 741. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Khoury and H. L. Weiner Multiple Sclerosis: What Have We Learned From Magnetic Resonance Imaging Studies? Arch Intern Med, March 23, 1998; 158(6): 565 - 573. [Abstract] [Full Text] [PDF] |
||||
![]() |
N Tubridy, H J Ader, F Barkhof, A J Thompson, and D H Miller Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups J. Neurol. Neurosurg. Psychiatry, January 1, 1998; 64(1): 50 - 55. [Abstract] [Full Text] |
||||
![]() |
M. D. Carrithers Immune Cell Traffic in the Brain: Blundering and Migration of Autoreactive T Lymphocytes Neuroscientist, July 1, 1997; 3(4): 207 - 210. [Abstract] [PDF] |
||||
![]() |
D. E. Goodkin, R. A. Rudick, and J. S. Ross The Use of Brain Magnetic Resonance Imaging in Multiple Sclerosis Arch Neurol, May 1, 1994; 51(5): 505 - 516. [Abstract] [PDF] |
||||
![]() |
R. Capra, N. Marciano, L. A. Vignolo, A. Chiesa, and R. Gasparotti Gadolinium--Pentetic Acid Magnetic Resonance Imaging in Patients With Relapsing Remitting Multiple Sclerosis Arch Neurol, July 1, 1992; 49(7): 687 - 689. [Abstract] [PDF] |
||||


















